A Trial of ABI-010 & ABI-007 in Patients With Advanced Non-Hematologic Malignancies
Phase 1 Withdrawn
17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
Phase 2 Completed
17 enrolled 6 charts
Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer
Phase 2 Completed
41 enrolled 10 charts
Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer
Phase 2 Terminated
11 enrolled 6 charts
TIME-2
Phase 2/3 Completed
22 enrolled
Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
Phase 2 Completed
43 enrolled
Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin
Phase 1/2 Completed
25 enrolled
Clinical Trial of Continuing Treatment for Patients Who Have Participated on a Prior Protocol Investigating Tanespimycin
Phase 2 Completed
6 enrolled
A Phase 1 Dose Escalation Study of IPI-493
Phase 1 Terminated
53 enrolled
Dose Escalation of IPI-493 in Hematologic Malignancies
Phase 1 Terminated
4 enrolled
Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma
Phase 2 Withdrawn
Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer
Phase 1/2 Completed
47 enrolled
Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer
Phase 2 Completed
21 enrolled 9 charts
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
Phase 1 Completed
80 enrolled
17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid Tumors
Phase 1 Completed
54 enrolled
17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma
Phase 2 Completed
22 enrolled 5 charts
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
Phase 2 Completed
226 enrolled
Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
Phase 1 Terminated
36 enrolled
Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Phase 1 Terminated
45 enrolled
Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes
Phase 1 Completed
42 enrolled
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate
Phase 1 Completed
Geldanamycin Analogue in Treating Patients With Advanced Cancer
Phase 1 Completed
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Malignant Melanoma
Phase 2 Completed
25 enrolled
Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer
Phase 1 Completed
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Kidney Cancer
Phase 2 Completed
Tanespimycin, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
78 enrolled
Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors
Phase 1 Completed
70 enrolled
17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia
Phase 1 Terminated
30 enrolled
17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
Phase 1 Terminated
74 enrolled
17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Phase 1 Completed
48 enrolled
PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma
Phase 1 Terminated
36 enrolled
Tanespimycin in Treating Patients With Stage III-IV Melanoma
Phase 2 Terminated
50 enrolled
Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia
Phase 1 Completed
Sorafenib and Bortezomib in Treating Patients With Advanced Cancer
Phase 1 Completed
50 enrolled
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
Phase 1 Completed
60 enrolled
17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor
Phase 1 Completed
35 enrolled
IPI-504-04
Phase 2 Completed
19 enrolled
Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib
Phase 3 Terminated
47 enrolled
Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer
Phase 2 Terminated
29 enrolled
Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)
Phase 1/2 Completed
88 enrolled
A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma
Phase 2 Terminated
1 enrolled
17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease
Phase 2 Completed
9 enrolled 8 charts
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis
Phase 2 Completed
37 enrolled
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery
Phase 1 Completed
BMS TIME-1
Phase 3 Completed
31 enrolled
Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)
Phase 1 Completed
63 enrolled
Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL
Phase 1 Terminated
10 enrolled
A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer
Phase 1/2 Withdrawn
56 enrolled
IPi-504-01
Phase 1 Completed
18 enrolled